Observational studies of psychiatric diseases such as schizophrenia, bipolar disorder and major depression have long tied ...

A new medical study out of Johns Hopkins University could potentially be a game changer for those suffering certain mental ...

Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be answered about scalability and costs, experts say.

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...

A new study published in Nature Mental Health has found that people with a higher genetic risk for schizophrenia tend to have ...

Titusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...

The most effective antipsychotic drug for people with treatment-resistant schizophrenia is clozapine. Yet, across the world, ...

Latest research at the Epilepsy Society using pioneering research equipment has shown parallels between people with ...

Receiving a schizophrenia diagnosis can be devastating. Many are unaware they are sick, refusing medication, temporarily unable to work, and disjointed from friends.

Johnson & Johnson submits sNDA to US FDA for Caplyta for prevention of relapse in schizophrenia: Titusville, New Jersey Wednesday, July 9, 2025, 14:00 Hrs [IST] Johnson & Johnson ...

Johnson & Johnson (NYSE: JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced the submission of a supplemental New Drug Application/sNDA to the US FDA for ...